218 related articles for article (PubMed ID: 11227395)
1. Olanzapine versus risperidone. A prospective comparison of clinical and economic outcomes in schizophrenia.
Edgell ET; Andersen SW; Johnstone BM; Dulisse B; Revicki D; Breier A
Pharmacoeconomics; 2000 Dec; 18(6):567-79. PubMed ID: 11227395
[TBL] [Abstract][Full Text] [Related]
2. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
Hamilton SH; Revicki DA; Edgell ET; Genduso LA; Tollefson G
Pharmacoeconomics; 1999 May; 15(5):469-80. PubMed ID: 10537964
[TBL] [Abstract][Full Text] [Related]
3. Olanzapine: an updated review of its use in the management of schizophrenia.
Bhana N; Foster RH; Olney R; Plosker GL
Drugs; 2001; 61(1):111-61. PubMed ID: 11217867
[TBL] [Abstract][Full Text] [Related]
4. Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand.
Gureje O; Miles W; Keks N; Grainger D; Lambert T; McGrath J; Tran P; Catts S; Fraser A; Hustig H; Andersen S; Crawford AM
Schizophr Res; 2003 Jun; 61(2-3):303-14. PubMed ID: 12729882
[TBL] [Abstract][Full Text] [Related]
5. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
6. A retrospective economic evaluation of olanzapine versus risperidone in the treatment of schizophrenia.
Zhao Z
Manag Care Interface; 2002 Feb; 15(2):75-81. PubMed ID: 11875967
[TBL] [Abstract][Full Text] [Related]
7. Risperidone olanzapine drug outcomes studies in schizophrenia (RODOS): health economic results of an international naturalistic study.
Kasper S; Jones M; Duchesne I;
Int Clin Psychopharmacol; 2001 Jul; 16(4):189-96. PubMed ID: 11459332
[TBL] [Abstract][Full Text] [Related]
8. Cost evaluation of risperidone compared with olanzapine.
Byerly MJ; Weber M; Brooks D; Casey SB; Elliot S; Hawkins J
Psychiatr Serv; 2003 May; 54(5):742-4. PubMed ID: 12719509
[TBL] [Abstract][Full Text] [Related]
9. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients.
Rascati KL; Johnsrud MT; Crismon ML; Lage MJ; Barber BL
Pharmacoeconomics; 2003; 21(10):683-97. PubMed ID: 12828491
[TBL] [Abstract][Full Text] [Related]
10. Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine.
Kelly DL; Nelson MW; Love RC; Yu Y; Conley RR
Psychiatr Serv; 2001 May; 52(5):676-8. PubMed ID: 11331805
[TBL] [Abstract][Full Text] [Related]
11. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
12. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Tran PV; Hamilton SH; Kuntz AJ; Potvin JH; Andersen SW; Beasley C; Tollefson GD
J Clin Psychopharmacol; 1997 Oct; 17(5):407-18. PubMed ID: 9315992
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
[TBL] [Abstract][Full Text] [Related]
14. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone or olanzapine.
Procyshyn RM; Zerjav S
Clin Ther; 1998; 20(6):1203-17; discussion 1192-3. PubMed ID: 9916613
[TBL] [Abstract][Full Text] [Related]
15. Olanzapine. A pharmacoeconomic review of its use in schizophrenia.
Foster RH; Goa KL
Pharmacoeconomics; 1999 Jun; 15(6):611-40. PubMed ID: 10538333
[TBL] [Abstract][Full Text] [Related]
16. Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
Feldman PD; Kaiser CJ; Kennedy JS; Sutton VK; Tran PV; Tollefson GD; Zhang F; Breier A
J Clin Psychiatry; 2003 Sep; 64(9):998-1004. PubMed ID: 14628974
[TBL] [Abstract][Full Text] [Related]
17. Pharmacy cost evaluation of risperidone, olanzapine, and quetiapine for the treatment of schizophrenia in acute care inpatient settings.
Mladsi DM; Grogg AL; Irish WD; Lopez RB; Degen K; Swann A; Nimsch CT
Curr Med Res Opin; 2004 Dec; 20(12):1883-93. PubMed ID: 15701206
[TBL] [Abstract][Full Text] [Related]
18. Service use and costs of treating schizophrenia with atypical antipsychotics.
Lewis M; McCrone P; Frangou S
J Clin Psychiatry; 2001 Oct; 62(10):749-56. PubMed ID: 11816863
[TBL] [Abstract][Full Text] [Related]
19. Association of co-morbidities with prescribing patterns and cost savings: olanzapine versus risperidone for schizophrenia.
Yu W; Ren XS; Lee AF; Herz L; Huang YH; Kazis LE
Pharmacoeconomics; 2006; 24(12):1233-48. PubMed ID: 17129077
[TBL] [Abstract][Full Text] [Related]
20. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
